Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT00624338
Show Display Options
Rank Status Study
1 Completed Atacicept Phase II/III in Generalized Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus, SLE
Interventions: Drug: Atacicept 75mg;   Drug: Atacicept 150mg;   Other: Placebo Comparator

Indicates status has not been verified in more than two years